You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Embedded Sensors for Flight Test (Every Aircraft a Test Aircraft)
SBC: NEXTGEN AERONAUTICS, INC. Topic: AF14AT01Increasing system capabilities in terms of weapon systems, ISR payloads, GNC, etc., enabled by smaller and more capable electronics systems have led to a trend for overall size reduction in military aircraft. This has resulted in a reduction in the avail...
STTR Phase II 2016 Department of DefenseAir Force -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors
SBC: NEONC TECHNOLOGIES INC Topic: BTDESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel Assay System and Analysis Algorithm in Detecting RNA Editing Events and Linked Splicing Isoforms
SBC: Celetrix LLC Topic: NIDAAbstract RNA editing is a process in which the genome encoded information is altered in RNA RNA editing is an efficient way to increase RNA complexity thereby fine tuning both gene function and dosage Adenosine to Inosine A to I editing is the most common type of RNA editing known in animals The cellular machinery recognizes inosine as guanosine so A to I editing of codons and splicing sign ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
SBC: BIOVINC, LLC Topic: NIDCRDESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Vaccines by Targeting Dendritic Cells with IFNa and IFNb Inducing Adjuvants
SBC: PARABON NANOLABS, INC. Topic: NIAIDDESCRIPTION provided by applicant There is a critical need for a safe and effective vaccine against HIV Decades of work have been invested in understanding the immune response to infection and different approaches have been taken to develop vaccines that are effective in preventing and treating the disease While effective in animal models none have been as effective in humans The immune ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
development of immunodeficient rabbit models
SBC: Celetrix LLC Topic: NIAIDDESCRIPTION provided by applicant Transplantation of human or animal pluripotent stem cells PSCs or their derivatives to model animals constitutes an important preclinical system to model and investigate cell survival development and differentiation in vivo and to assess the safety and efficacy of transplantation based cell therapies Immunodeficient mice are dominantly used in biomedical ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An epitope focused nanoparticle vaccine for MRSA and biodefense
SBC: VLP BIOTECH, INC. Topic: NIAIDDESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
"Extra Innings”: Using Serious Gaming and the Science of Baseball to Teach Science and Mathematics
SBC: DFUSION INC. Topic: 999DESCRIPTION provided by applicant Due to the rapid advances in science technology engineering and mathematics STEM the United States has been at the forefront of innovation and technology development in the science health and biomedical fields However these continuing advances are in jeopardy as there is a growing national shortage of trained STEM workers While the need for a STEM li ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
SBC: VIROGENICS, INC. Topic: NIAIDDESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health